B2B
Neuvasq
Gosselies, Belgiumneuvasq.com
Neuvasq develops first-in-class Wnt surrogate antibodies targeting Gpr124 and Reck to restore the integrity of blood-brain and blood-retina barriers, aiming to treat neurological and vascular retinal
aliveseries-a
series-a
Stage
1
Funding Rounds
About
Neuvasq develops first-in-class Wnt surrogate antibodies targeting Gpr124 and Reck to restore the integrity of blood-brain and blood-retina barriers, aiming to treat neurological and vascular retinal disorders.
Explore Neuvasq's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.